Results 31 to 40 of about 215,114 (209)
Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals
Central European Journal of Immunology, 2021 Chronic hepatitis C (CHC) affects the activity of natural killer (NK) cells, but successful interferon- free treatment partially restores it. The goal of this study was to assess whether gender influences NK functionality.Agata Zientarska, Justyna Mikuła-Pietrasik, Mariusz Kaczmarek, Aleksandra Witkowska, Błażej Rozpłochowski, Arleta Kowala-Piaskowska, Krzysztof Książek, Jan Żeromski, Iwona Mozer-Lisewska +8 moredoaj +1 more sourceAntiviral therapy of chronic hepatitis C: 30 years success story [PDF]
Терапевтический архив, 2019 Exactly 30 years ago, hepatitis C virus was identified. Over the years, tremendous success has been achieved in the treatment of hepatitis C, which is currently considered to be an almost completely curable disease. The review presents the main stages in D T Abdurakhmanov, T P Rozina, E N Nikulkina, E Z Burnevich, E L Tanashuk, M V Severov, A L Filatova, S Yu Milovanova, V V Karpov, S V Moiseev +9 moredoaj +1 more sourceHCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]
, 2013 UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is Dillon, John, Hellard, M, Grebely, J ; https://orcid.org/, Hellard, Margaret, Goldberg, David J., Martin, Natasha K, Goldberg, DJ, Vickerman, P, Dore, Gregory J, Goldberg, David, Hickman, M ; https://orcid.org/, Hickman, Matthew, Lima, Viviane D, Grebely, J, Hutchinson, SJ, Dillon, John F.; id_orcid, Foster, Graham R., Lima, Viviane, Hickman, M, Martin, Natasha, Hutchinson, Sharon J.; id_orcid, Lima, VD, Martin, NK, Dore, Gregory J., Foster, Graham, Lima, Viviane D., Dore, Gregory, Vickerman, Peter, Goldberg, David J, Dillon, John F, Grebely, Jason, Hutchinson, Sharon, Hutchinson, Sharon J., Foster, Graham R, Dillon, JF, Dore, GJ ; https://orcid.org/, Foster, GR, Dillon, John F., Dore, GJ, Hutchinson, Sharon J, Martin, Natasha K. +40 morecore +1 more sourceEffect of combined siRNA of HCV E2 gene and HCV receptors against HCV [PDF]
Virology Journal, 2011 Hepatitis C virus (HCV) is a major threat as almost 3% of the world's population (350 million individual) and 10% of the Pakistani population is chronically infected with this virus. RNA interference (RNAi), a sequence-specific degradation process of RNA, has potential to be used as a powerful alternative molecular therapeutic approach in spite of the ...Ashfaq Usman Alli A, Ahmad Waqar, Khan Mahwish, Ijaz Bushra, Samreen Baila, Khaliq Saba, Jahan Shah, Hassan Sajida +7 moreopenaire +3 more sourcesAccelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study
Virulence, 2021 Involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT, i.e., visfatin or pre-B-cell colony-enhancing factor), a cancer metabokine, in chronically hepatitis C virus (HCV)-infected (CHC) patients with sustained virological responses ...Ming-Ling Chang, Yu-Sheng Lin, Ming-Yu Chang, Chia-Lin Hsu, Rong-Nan Chien, Cathy SJ Fann +5 moredoaj +1 more sourceSox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks
Virulence, 2021 Toll-like receptors (TLRs) are essential for the protection of the host from pathogen infections by initiating the integration of contextual cues to regulate inflammation and immunity.Jian Shang, Yuan Zheng, Jiayin Mo, Wenbiao Wang, Zhen Luo, Yongkui Li, Xulin Chen, Qiwei Zhang, Kailang Wu, Weiyong Liu, Jianguo Wu +10 moredoaj +1 more sourceHCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe
HIV Medicine, 2021 AbstractObjectivesAlthough direct‐acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV‐coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV‐coinfected individuals in Europe.MethodsFactors associated with odds of Amele S., Sandri A. K., Rodger A., Vandekerckhove L., Benfield T., Milinkovic A., Duvivier C., Stellbrink H. -J., Sambatakou H., Chkhartishvili N., Caldeira L., Laguno M., Domingo P., Wandeler G., Gisinger M., Kuzovatova E., Dragovic G., Knysz B., Matulionyte R., Rockstroh J. K., Lundgren J. D., Mocroft A., Peters L., Harxhi A., Losso M., Kundro M., Schmied B., Zangerle R., Karpov I., Vassilenko A., Mitsura V. M., Paduto D., Clumeck N., Wit S. D., Delforge M., Florence E., Vandekerckhove L., Hadziosmanovic V., Begovac J., Machala L., Jilich D., Sedlacek D., Kronborg G., Benfield T., Gerstoft J., Katzenstein T., Pedersen C., Johansen I. S., Ostergaard L., Wiese L., Moller N. F., Nielsen L. N., Zilmer K., Smidt J., Aho I., Viard J. -P., Girard P. -M., Pradier C., Fontas E., Duvivier C., Rockstroh J., Behrens G., Degen O., Stellbrink H. J., Stefan C., Bogner J., Fatkenheuer G., Chkhartishvili N., Sambatakou H., Adamis G., Paissios N., Szlavik J., Gottfredsson M., Devitt E., Tau L., Turner D., Burke M., Shahar E., Hassoun G., Elinav H., Haouzi M., Elbirt D., D'Arminio Monforte A., Esposito R., Mazeu I., Mussini C., Mazzotta F., Gabbuti A., Lazzarin A., Castagna A., Gianotti N., Galli M., Ridolfo A., Sacco L., Uzdaviniene V., Matulionyte R., Staub T., Hemmer R., Dragas S., Stevanovic M., Reiss P., Trajanovska J., Reikvam D. H., Maeland A., Bruun J., Knysz B., Gasiorowski J., Inglot M., Bakowska E., Flisiak R., Grzeszczuk A., Parczewski M., Maciejewska K., Aksak-Was B., Beniowski M., Mularska E., Jablonowska E., Kamerys J., Wojcik K., Mozer-Lisewska I., Rozplochowski B., Zagalo A., Mansinho K., Maltez F., Radoi R., Oprea C., Davila C., Yakovlev A., Trofimora T., Khromova I., Kuzovatova E., Blokhina I. N., Novogrod N., Borodulina E., Vdoushkina E., Ranin J., Tomazic J., Miro J. M., Miro J. M., Martinez E., Garcia F., Blanco J. L., Martinez-Rebollar M., Mallolas J., Callau P., Rojas J., Inciarta A., Moreno S., del Campo S., Clotet B., Jou A., Paredes R., Puig J., Llibre J. M., Santos J. R., Domingo P., Gutierrez M., Mateo G., Sambeat M. A., Laporte J. M., Falconer K., Thalme A., Sonnerborg A., Brannstrom J., Flamholc L., Scherrer A., Weber R., Cavassini M., Calmy A., Furrer H., Battegay M., Schmid P., Kuznetsova A., Mikhalik J., Sluzhynska M., Milinkovic A., Johnson A. M., Simons E., Edwards S., Phillips A., Johnson M. A., Mocroft A., Orkin C., Winston A., Clarke A., Leen C., Karpov I., Losso M., Lundgren J., Rockstroh J., Aho I., Rasmussen L. D., Svedhem V., Wandeler G., Pradier C., Chkhartishvili N., Matulionyte R., Oprea C., Kowalska J. D., Begovac J. +199 moreopenaire +7 more sourcesResponse prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms [PDF]
, 2011 Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C.Askarieh Galia, Neumann, A.U. (Avidan), Söderholm, Jonas,, Magnus Lindh, Avidan U Neumann, Stephanie Bibert, Soderholm, J, Askarieh, Galia,, Romero, A. (Ana), Group, DITTO-HCV Study, Jean-Michel Pawlotsky, Lindh, M., Negro, F, Söderholm, J., Lindh, M, Missale, Gabriele, Lagging, Martin,, Askarieh, G., Haagmans, Bart L, Romero, Ana, Hellstrand, K. (Kristoffer), Bochud Pierre-Yves, Lagging, Martin, Romero, A, null null, Söderholm Jonas, Haagmans, Bart L., Neumann, AU (Avidan), Gabriele Missale, Ferrari, C., Negro, F., Pawlotsky, J.M., Lindh Magnus, Negro Francesco, Avidan U. Neumann, Pierre-Yves Bochud, Lindh, Magnus, Johan Westin, Zeuzem Stefan, Lindh, M. (Magnus), Missale Gabriele, Bochud, Pierre Yves, Bibert, S., Bochud, P.Y., Galia Askarieh, Lagging Martin, Ferrari Carlo, Bibert, Stephanie, Hellstrand, Kristoffer, Zeuzem, S., Neumann, Avidan U., Haagmans, B.L., DITTO-HCV Study Group, Neumann, A.U., Lindh, Magnus,, Francesco Negro, Westin, J., Söderholm, J. (Jonas), Zeuzem, S. (Stefan), Söderholm, Jonas, Ferrari, Carlo, Martin Lagging, Neumann Avidan U., Zeuzem, Stefan, Neumann, Avidan U, Zeuzem, S, Hellstrand Kristoffer, Westin, Johan, Bart L Haagmans, Romero, A., Lagging, M. (Martin), Hellstrand, K., Haagmans, Bart, Bibert Stephanie, Hellstrand, K, Bart L. Haagmans, Missale, G. (Gabriele), Pawlotsky, Jean Michel, Pawlotsky, Jean-Michel, Ferrari, C. (Carlo), Carlo Ferrari, Bochud, P-Y. (Pierre-Yves), Haagmans Bart L., Askarieh, G, Lagging, M., Missale, G., Stefan Zeuzem, Kristoffer Hellstrand, Ferrari, C, Westin, J. (Johan), Askarieh, Galia, Bibert, S, Lagging, M, Westin, Johan,, Hellstrand, Kristoffer,, Westin, J, Haagmans, B.L. (Bart), Romero Ana, Jonas Söderholm, Pawlotsky Jean-Michel, Westin Johan, Askarieh, G. (Galia), Negro, Francesco, Bochud, PY, Bochud, Pierre-Yves, Pawlotsky, JM, Pawlotsky, J-M. (Jean-Michel), Missale, G, Romero, Ana,, Ana Romero +109 morecore +1 more source
